这一医疗创新不仅缓解了病理专家资源紧缺的矛盾，更推动了病理诊断从"经验驱动"走向"智能赋能"。 在病理检测和医疗数据上，麦克奥迪发挥平台、技术与医疗资源优势；智能院集团则依托北京人工智能 数据训练基地和"数算模用一体化"体系，与医疗领域进行深度融合，使模型能够在真实临床场景中落地 应用。 2025年9月17日—21日，第22届中国-东盟博览会在广西南宁举行。18日，由麦克奥迪(300341)与北京亦 庄智能城市研究院集团有限公司（简称"智能院集团"）联合研发的胃癌病理诊断垂域模型V1首次正式 发布。本次合作是"医疗+科技"跨界融合的一次创新实践，标志着人工智能在医疗病理应用中实现又一 突破。 发布会上，麦克奥迪财务总监刘亚军与智能院集团副总经理朱璐璐先后发表主题演讲。发布会上，刘亚 军系统介绍了麦克奥迪"智能电气、智慧光学、数智医疗"三大核心业务板块，全面展现了在能源管理、 光学创新和数字病理全价值链的深厚积累与发展蓝图。朱璐璐则从产业视角出发，详细阐释了以算力聚 生态、以生态汇数据、以数据育模型、以模型促应用、以应用哺算力，形成"数算模用"相互支撑、互为 依托的发展新模式。双方依托各自优势，共研共创胃癌病理 ...

Group 1 - Qilu Bank has achieved impressive mid-year results for 2025, establishing a comprehensive financial service ecosystem to support private enterprises in overcoming financing burdens and accelerating development [1] - The bank aims to be a key player in serving the private economy by innovatively creating an "industrial service circle" to eliminate invisible financing barriers [1] - Many private enterprises express gratitude for Qilu Bank's support, stating that it has strengthened their confidence in securing orders [1] Group 2 - The 2025 Marine Cooperation Development Forum highlighted the focus on marine economy, with Jiaozhou Bay becoming a significant cold chain logistics base for aquatic products [3] - A leading cold chain enterprise in the region has a cold storage area of 32,000 square meters and can handle 180,000 tons of aquatic products annually, covering a wide market [3][4] - Before receiving credit support, this enterprise faced development bottlenecks due to high capital turnover pressure, which limited its ability to expand supplier relationships [4] Group 3 - Qilu Bank has introduced a "blue cold chain industry chain financial solution" to address funding bottlenecks in the cold chain industry, utilizing the creditworthiness of a leading enterprise [4] - The bank provided 50 million yuan in online trade financing to a supply chain management company, reducing financing costs by 750,000 yuan annually [4][5] - The utilization rate of the cold storage facility increased from 90% to 98%, and the maximum daily throughput exceeded 800 tons, establishing it as a busy cold chain hub [5] Group 4 - Qilu Bank is focusing on technology finance, having successfully provided 3 million yuan in financing to a transportation facility company that signed orders worth over 90 million yuan [6][7] - The bank has developed a credit evaluation system based on big data for technology enterprises, allowing for the monetization of their technological strengths [7] - As of June, the bank's technology loans balance reached 2.18 billion yuan, reflecting a 30% increase since the beginning of the year [7] Group 5 - Qilu Bank launched an innovative "non-recourse domestic factoring" product to help small and micro enterprises address financing challenges related to accounts receivable [8][9] - The bank facilitated over 76 million yuan in loans through the "泉信链" product, assisting nearly 170 private enterprises in overcoming accounts receivable financing difficulties [9]

AI的核心能力在于整合多源、动态、连续的个体数据，并通过算法挖掘数据背后的隐含关联，将"数据 碎片"转化为"健康画像"，进而推动健康服务从"标准化"向"个性化"转型。但当前AI发展，单一数据局 限仍有待打破。 吴文达亦表示，AI并非无所不能的，对AI能力要有清醒的认知，医生要严格遵守AI的边界。"AI的发 展，可以给医疗体系发展带来很多获益，但要保持正常运作，需要建立健全的风险管理和责任机制。" AI正在加速渗透进医疗行业，但如何理性看待它的边界，同样需要引起重视。 近日，在2025腾讯全球数字生态大会上，腾讯健康总裁、腾讯生命科学实验室负责人、腾讯健康普惠实 验室负责人吴文达表示，AI+医疗健康正迈入一个新的阶段，AI从根本上改变人们管理和维护健康的方 式，使得健康管理变得更个性化、预测性和参与性。 在吴文达看来，推动人工智能+医疗健康行业可持续发展，要关注七个关键路标，包括要构建可信AI、 加速AI多模态发展、从被动治疗转向主动健康管理、革新生命科学研究范式、助力医疗资源再分配、 促进复合型医疗人才再生、重视伦理治理。 大模型可能会出现幻觉问题，在医疗行业，如果造成错误决定的话，会影响到生命健康。 "多维 ...

秋意初显的南京，正迎来一场跨越山海的经贸盛会。 9月17日上午，第五届Innovation Fair欧洲企业南京行暨跨境产业合作对接会拉开帷幕。来自德 国、荷兰、西班牙、意大利、英国等14个国家的百余家经贸组织齐聚南京，围绕跨境贸易投资、智能 制造、软件信息、人工智能、生物健康等重点领域，开展精准对接与深度对话，探索中欧产业合作新路 径。 记者从现场获悉，欧洲已成为南京第三大投资来源地，欧洲企业累计在宁投资项目1224个，众多 知名企业在此深耕布局。时值中欧建交50周年的历史性时刻，众多欧洲企业再度带着技术、资金与诚 意而来，主动融入中国市场的澎湃浪潮，而南京也将以更崭新的姿态、更开放的理念向欧洲伙伴敞开怀 抱，共同书写互利共赢、合作创新的崭新篇章。 多元需求折射强大引力 "此次参会的荷兰代表团来自全球创新的前沿，希望在此将荷兰高科技生态系统的独特优势与中国 机遇链接起来，激发新的合作伙伴关系，并探索出创造性的解决方案。"在开幕致辞中，荷兰王国驻上 海总领事馆总领事孔思哲的这番话，道出不少欧洲企业的心声。 从寻求市场、技术合作，到对接资本、布局供应链，欧洲企业此行目的多元、方向清晰，折射出中 国在全球经济格局 ...

Group 1 - The core viewpoint of the news highlights the recent trading performance and financial metrics of Furuya Co., indicating a significant increase in financing activities and stockholder engagement [1][2]. - On September 17, Furuya Co. saw a stock price increase of 2.36% with a trading volume of 1.473 billion yuan, and a net financing purchase of 64.34 million yuan [1]. - As of September 17, the total financing and securities balance for Furuya Co. reached 1.197 billion yuan, which is at a high level compared to the past year [1]. Group 2 - As of September 10, the number of shareholders for Furuya Co. increased by 6.75% to 27,400, while the average circulating shares per person decreased by 6.33% to 8,532 shares [2]. - For the first half of 2025, Furuya Co. reported a revenue of 713 million yuan, reflecting a year-on-year growth of 11.02%, while the net profit attributable to shareholders decreased by 31.09% to 51.934 million yuan [2]. - Furuya Co. has distributed a total of 246 million yuan in dividends since its A-share listing, with 52.6106 million yuan distributed over the last three years [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 保荐人（主承销商）：中信证券股份有限公司 特别提示 敬请投资者重点关注本次发行的缴款环节，并于２０２５年９月１８日（Ｔ＋２日）及时履行缴款义 务，具体内容如下： １、网上投资者申购新股中签后，应根据本公告履行资金交收义务，确保其资金账户在２０２５年９月 １８日（Ｔ＋２日）日终有足额的新股认购资金，不足部分视为放弃认购，由此产生的后果及相关法律 责任由投资者自行承担。投资者款项划付需遵守投资者所在证券公司的相关规定。 ３、当出现网下和网上投资者缴款认购的股份数量合计不足扣除最终战略配售数量后本次公开发行数量 的７０％时，上海建发致新医疗科技集团股份有限公司（以下简称"建发致新"或"发行人"）和保荐人 （主承销商）中信证券股份有限公司（以下简称"中信证券"或"保荐人（主承销商）"）将中止本次新股 发行，并就中止发行的原因和后续安排进行信息披露。 ４、网上投资者连续１２个月内累计出现３次中签后未足额缴款的情形时，自结算参与人最近一次申报 其放弃认购的次日起６个月（按１８０个自然日计算，含次日）内不得参与新股、存托凭证、可转换公 司债券、可交换公司债券网上申购。放弃认 ...

证券时报记者卓泳 然而，这笔带着"枷锁"的资金，让不少企业陷入两难困境：迁址则会提高企业的综合运营成本，不迁址 很可能会错失这笔"救命钱"，尤其对现金流承压的企业而言，这种抉择更显艰难。 一边是地方推动产业落地的招商需求，一边是企业保障自身稳定发展的现实诉求，如何在二者之间找到 平衡点，成为当前亟待破解的关键问题。 企业"迁址" 与"返投"任务深度绑定 近两年，各地政府主动"挖企"的频次之高、力度之大远超预期，不少地方甚至一把手"挂帅"远赴千里之 外招揽优质企业，其核心诉求都是推动企业迁址，助力当地培育上市公司。 "来挖我们的城市很多，比如浙江、江苏，有的是市长带队过来的，一开始我们还以为是客户到门口 了，结果进来一看，才发现是政府的人。"深圳融昕医疗科技有限公司负责人杨宁近期在接受记者采访 时表示。 无独有偶，一家做影像技术的高新科技企业负责人张奇（化名）也对记者表示，同样是江浙地区，还有 部分中部省会城市想让他们去当地发展，"他们的诉求很明确，就是希望我们迁总部，成为当地的重点 企业。" "挖企"的背后，是VC/PE（风险投资与私募股权投资）机构一场浩浩荡荡的"返投"攻坚战。当前，政府 投资基金已成为一级 ...

Core Viewpoint - Shanghai RunDa Medical Technology Co., Ltd. has triggered the redemption clause for its convertible bonds due to stock price performance but has decided not to exercise this right at this time [1] Group 1: Redemption Clause Trigger - The company's stock has met the condition of closing prices being no less than 130% of the current conversion price for at least 15 out of 30 consecutive trading days from August 25 to September 17, 2025 [1] - The board of directors has decided not to exercise the early redemption right on September 17, 2025, and will also refrain from exercising this right for the next three months, from September 18 to December 17, 2025 [1] Group 2: Future Considerations - After December 17, 2025, if the redemption conditions are met again, the board will make a further decision regarding the redemption [1] - The relevant parties have not held the convertible bonds before the redemption conditions were met and have no plans to reduce their holdings in the next six months [1] Group 3: Convertible Bond Details - The "RunDa Convertible Bonds" were listed on July 13, 2020, with an initial conversion price of 13.36 yuan per share, which has been adjusted to 12.97 yuan per share [1]

Core Viewpoint - The 2025 Capital International Medical Conference emphasizes the importance of international collaboration in medical technology innovation, particularly between China and the UK, to enhance global health governance and address common health challenges [3][4][6]. Group 1: Conference Highlights - The conference was attended by over 1,500 leaders and experts, showcasing the commitment to advancing medical technology and health research [1]. - Keynote speeches included a presentation by Kamran Abassi, editor of the British Medical Journal, focusing on deepening Sino-British medical technology cooperation [3][4]. - The conference featured the release of the "2025 China Hospital Research Impact Report," which analyzes the citation of Chinese hospital research in global health policies and clinical guidelines over the past 20 years [5][6]. Group 2: Report Insights - The report covers the period from 2005 to 2024 and evaluates how research from selected hospitals translates into real-world impacts, highlighting the contributions of Chinese hospitals to global health policy [5][6]. - A total of 12,601 research outputs from Chinese hospitals were cited in health policies and clinical guidelines across over 75 countries, with a total citation count of 34,675 [5]. - The report underscores the growing international influence of Chinese medical research in shaping healthcare standards and improving patient outcomes globally [6]. Group 3: Collaborative Opportunities - The Sino-British Medical Technology Innovation Forum gathered policymakers, hospital managers, and medical researchers to discuss opportunities for collaboration in addressing shared healthcare challenges [7][8]. - Experts discussed the importance of data-driven approaches and the role of artificial intelligence in advancing medical innovation, while also acknowledging the challenges that lie ahead [8][9]. - The conference initiated a competition for innovative medical technology projects, aiming to foster an open and collaborative ecosystem for medical innovation in China [9].

证券代码：603205 证券简称：健尔康 公告编号：2025-025 健尔康医疗科技股份有限公司 第二届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 二、监事会会议审议情况 经全体监事审议，会议表决情况如下： （一）审议通过《关于免去监事会主席职务的议案》 根据《中华人民共和国公司法》《关于新＜公司法＞配套制度规则实施相关过渡期安排》《上市公司章 程指引》等相关法律法规的规定，结合公司实际情况，公司将不再设置监事会和监事，免去汤红芳女士 监事会主席的职务。 表决结果：3票同意，0票反对，0票弃权。 特此公告。 健尔康医疗科技股份有限公司 一、 监事会会议召开情况 健尔康医疗科技股份有限公司（以下简称"公司"）第二届监事会第九次会议于2025年9月16日以现场方 式在公司会议室召开，会议通知于2025年9月12日以书面等方式送达。本次会议由监事会主席汤红芳女 士主持，会议应到监事3人，实到监事3人。本次监事会的召集、召开和表决程序符合《中华人民共和国 公司法》等有关法律法规及《健尔康医疗科技股份有限公 ...